Homologous 131I fibrinogen and its purified antibody will concentrate in a major portion of the neoplasms of the dogs and humans into which they are injected, according to new data. This report gives the scintillation scanning results obtained after iv administration of 131I‐labeled and purified antihuman fibrinogen to 172 consecutive patients with various types of neoplasms. In 75% (129/172) of the cases the tumor, in various sites, was unequivocally located. These included mammary carcinomas (12/17), malignant melanoma (16/26), bronchogenic carcinoma (27/34), osteogenic sarcomas (9/9), hypernephromas (6/6), and primary tumors of the brain (10/18). The 131I deposition in tumor relative to normal tissue and blood was so great that in 12 terminal patients therapeutic trials were initiated using 100 to 160 me of the labeled antibody preparation. In some of these attempts, there was substantial remission of clinical symptoms. The usefulness of this technique for specific radiation therapy of tumors will be greatly improved when methods are developed for increasing 131I concentration in the peoplasm. Several approaches, including fever, endotoxin, pretreatment with fibrinolytic agents and post‐treatment with antifibrinolytic agents, are under intensive investigation in experiments and offer great promise.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.